Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...